Avanos Medical, Inc. (AVNS)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$24.99+0.04%
Close 2026-07-24 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · AVNS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 21.6% |
| Our one-year growth estimate | diamond | 2.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 19.2 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 88 industry peers · Company calendar date is not available
AVNS — M&A activity — Changes in Control of Registrant The information set forth in the Introductor…
Dated 2026-07-30
Changes in Control of Registrant The information set forth in the Introductory Note and in Items 2.01, 2.03, and 5.02 of this Current Report on Form 8-K is incorporated by reference in this
Why it matters: Improving cash flow is vital for Avanos to support growth and manage debt after the merger.
Supportive ifCash flow from operations turns positive, exceeding $10 million in the next quarter.
Worry ifCash flow from operations remains negative or worsens in the next quarter.
Why it matters: Stockholder approval is needed to complete the merger with American Industrial Partners. This will show if the acquisition goes as planned.
Supportive ifStockholders approve the merger at the special meeting on July 22, 2026.
Worry ifStockholders say no to the merger plan at the special meeting.
Why it matters: The meeting will decide on new board members. This affects governance and strategy.
Watch forNew board members are elected. This helps with governance and oversight.
Also watch forThe election of new board members fails or is delayed for an unknown time.
Why it matters: Completing the merger is a big change for Avanos. It may help its growth and innovation.
Supportive ifThe merger is completed by July 27, 2026, with all conditions satisfied.
Worry ifThe merger is delayed beyond July 27, 2026, due to unmet conditions.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$16 on $10,000 · ±0.2% | How much price usually moves either way. |
| Bad day | $300 loss on $10,000 · 3.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,619 loss on $10,000 · 16.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: New directors may change Avanos' growth plans and how the company operates.
Watch forThe new board members make changes that improve operations in six months.
Also watch forThere are no clear changes in strategy or performance after the new board members join.
Why it matters: Strong growth in this area is important for Avanos's overall success. It shows the strategy is working.
Supportive ifSpecialty Nutrition Systems revenue grows by more than 20% year over year in the next quarter.
Worry ifRevenue growth in Specialty Nutrition Systems falls below 10% year over year.
Why it matters: Revenue growth will show if Avanos is selling more after the merger announcement.
Supportive ifQ2 2026 revenue growth exceeds 8.8% year over year.
Worry ifIf Q2 2026 revenue growth is below 8.8% year over year, sales may face issues.